Literature DB >> 1617632

Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.

H Kobayashi1, H Ohi, M Sugimura, H Shinohara, T Fujii, T Terao.   

Abstract

HOC-I ovarian cancer cells express the single-chain form of the urokinase-type plasminogen activator (uPA) and cathepsin B (cath B) on their cell surface. The significance of the expression of cell surface uPA/cath B activity to the invasive potential was examined by preincubating with uPA/cath B-modulating agents in in vitro invasion assay. The anti-uPA monoclonal antibody 394 effectively inhibited invasion in a dose-dependent manner. On the contrary, anti-cath B antibody did not affect the invasive potential of the cells. E-64, a specific inhibitor for cysteine proteases, blocked invasion as effectively as monoclonal antibody 394. The data reveal that the uPA and cysteine proteases contribute significantly to the invasive capacity of the cells. We suggest that the cysteine proteases facilitate the action of uPA, possibly by activating proenzyme uPA produced by cancer cells. Evidence for the role of a cathepsin-uPA activation cascade in HOC-I cell invasion is provided.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617632

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

Authors:  D Morrissey; J O'Connell; D Lynch; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.

Authors:  D F Alonso; E F Farías; V Ladeda; L Davel; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

4.  Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.

Authors:  Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

5.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.

Authors:  C Collesi; M M Santoro; G Gaudino; P M Comoglio
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

7.  Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.

Authors:  C E Holmes; J E Levis; D L Ornstein
Journal:  Clin Exp Metastasis       Date:  2009-05-15       Impact factor: 5.150

8.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

9.  Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth.

Authors:  E Weber; D Günther; F Laube; B Wiederanders; H Kirschke
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.

Authors:  C Festuccia; V Dolo; F Guerra; S Violini; P Muzi; A Pavan; M Bologna
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.